Topadur Pharma

Zurich-Schlieren, Switzerland, 2 November 2023

We are pleased to announce that TOPADUR PHARMA AG has been awarded an Innosuisse grant to fund our collaborative project with partners from Yonsei University and Juvic Inc. in South Korea. The project aims to develop new technologies for the treatment of systemic sclerosis. We thank Innosuisse and the Korea Institute for Advancement of Technology (KIAT) for their support.

‍

Download Document Dokument herunterladen

1.7.21

Press Release

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces the submission of an application to the European Medicines Agency to receive Orphan Drug Designation Status.

10.11.20

Press Release

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR announces positive results from an interim analysis of Phase I clinical trial with their new wound healing drug candidate.

5.10.21

Press Release

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

Contact

TOPADUR, Yonsei University and Juvic Inc. grant awarded

TOPADUR submits an Orphan Drug Designation application for TOP-N53

TOPADUR announces positive results from an interim analysis of Phase I trial

TOPADUR Pharma AG announces positive results from TOP-N53 First-in-Human Study

Investors

About us

Pipeline

Contact